TrialAnnals of the rheumatic diseases2022

Tofacitinib and risk of cardiovascular outcomes: results from the Safety of TofAcitinib in Routine care patients with Rheumatoid Arthritis (STAR-RA) study.

Farzin Khosrow-Khavar et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.